T. W. Chun, L. Stuyver, S. B. Mizell, L. A. Ehler, J. A. Mican, M. Baseler, A. L. Lloyd, M. A. Nowak and A. S. Fauci, “Presence of an Inducible HIV1 Latent Reservoir During Highly Active Antiretroviral Therapy,” Proceedings of the National Academy of Sciences, Vol. 94, No. 24, 1997, pp. 1319313197.
 D. Finzi, M. Hermankova, T. Pierson, L. M. Carruth, C. Buck, R. E. Chaisson, T. C. Quinn, K. Chadwick, J. Margolick, R. Brookmeyer, et al., “Identification of a Reservoir for HIV1 in Patients on Highly Active Antiretroviral Therapy,” Science, Vol. 278, No. 5341, 1997, pp. 12951300
 J. K. Wong, M. Hezareh, H. F. Gunthard, D. V. Havlir, C. C. Ignacio, C. A. Spina and D. D. Richman, “Recovery of ReplicationCompetent HIV Despite Prolonged Suppression of Plasma Viremia,” Science, Vol. 278, No. 5341, 1997, pp. 12911295.
 M. M. Hadjiandreou, R. Conejeros and V. S. Vassiliadis, “Towards a LongTerm Model Construction for the Dynamic Simulation of HIV Infection,” Mathematical Biosciences and Engineering, Vol. 4, No. 3, 2007, pp. 489 504.
 A. S. Perelson, A. U. Neumann, M. Markowitz, et al., “HIV1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell LifeSpan, and Viral Generation Time,” Science, Vol. 271, No. 5255, 1996, pp. 15821586.
 A. Landi, A. Mazzoldi, C. Andreoni, M. Bianchi, A. Cavallini, M. Laurino, L. Ricotti, R. Iuliano, B. Matteoli and L. CeccheriniNelli, “Modelling and Control of HIV Dynamics,” Computer Methods and Programs in Biomedicine, Vol. 89, No. 2, 2008, pp. 162168.
 M. M. Hadjiandreou, R. Conejeros and D. I. Wilson, “LongTerm HIV Dynamics Subject to Continuous The rapy and Structured Treatment Interruptions,” Chemical Engineering Science, Vol. 64, No. 7, 2009, pp. 1600 1617.
 A. Heydari, M. H. Farahi and A. A. Heydari, “Chemotherapy in an HIV Model by a Pair of Optimal Control,” Proceedings of the 7th WSEAS International Conference on Simulation, Modelling and Optimization, Beijing, 2007, pp. 5863.
 B. M. Adams, H. T. Banks, H. D. Kwon and H. T. Tran, “Dynamic Multidrug Therapies for HIV: Optimal and STI Control Approaches,” Mathematical Biosciences and Engineering, Vol. 1, No. 2, 2004, pp. 223241.
 F. Neri, J. Toivanen and R. A. E. M?kinen, “An Adaptive Evolutionary Algorithm with Intelligent Mutation Local Searchers for Designing Multidrug Therapies for HIV,” Applied Intelligence, Vol. 27, No. 3, 2007, pp. 219235.
 C. D. Myburgh and K. H. Wong, “An Optimal Control Approach to Therapeutic Intervention in HIV Infected Individuals,” Proceedings of the Third International Conference on Control Theory and Applications, Pretoria, South Africa, 2001.
 B. M. Adams, H. T. Banks, M. Davidian, H. D. Kwon, H. T. Tran, S. N. Wynne and E. S. Rosenberg, “HIV Dynamics: Modeling, Data Analysis, and Optimal Treatment Protocols,” Journal of Computational and Applied Math ematics, Vol. 184, No. 1, 2005, pp. 1049.
 S. Butler, D. Kirschner and S. Lenhart, “Optimal Control of Chemotherapy Affecting the Infectivity of HIV,” In: O. Arino, D. Axelrod, M. Kimmel and M. Langlais, Eds., Advances in Mathematical Population Dynamics: Molecules, Cells, Man, World Scientific, Singapore, pp.104 120.
 H. Shim, S. J. Han, C. C. Chung, S. Nam and J. H. Seo, “Optimal Scheduling of Drug Treatment for HIV Infection: Continuous dose Control and Receding Horizon Control,” International Journal of Control, Automation, and Systems, Vol. 1, No. 3, 2003, pp. 401407.
 D. Kirschner, S. Lenhart and S. Serbin, “Optimal Control of the Chemotherapy of HIV Infection: Scheduling, Amounts and Initiation of Treatment,” Journal of Mathematical Biology, Vol. 35, No. 7, 1997, pp. 775792.
 U. Ledzewicz and H. Sch?ttler, “On Optimal Controls for a General Mathematical Model for Chemotherapy of HIV,” Proceedings of the 2002 American Control Conference, Anchorage, Vol. 5, 2002, pp. 34543459.
 R. Zurakowski, M. J. Messina, S. E. Tuna and A. R. Teel, “HIV Treatment Scheduling Via Robust Nonlinear Model Predictive Control,” Proceedings of the 5th Asian Control Conference, Melbourne, Vol. 1, 2004, pp. 2532.
 R. Zurakowski and A. R. Teel, “Enhancing Immune Response to HIV Infection Using MPCBased Treatment Scheduling,” Proceedings of the 2003 American Control Conference, Denver, Vol. 2, 2003, pp. 11821187.
 R. Zurakowski, A. R. Teel and D. Wodarz, “Utilizing Alternate Target Cells in Treating HIV Infection through Scheduled Treatment Interruptions,” Proceedings of the 2004 American Control Conference, Melbourne, Vol. 1, 2004, pp. 946951.
 H. T. Banks, H. D. Kwon, J. Toivanen and H. T. Tran, “An State Dependent Riccati Equation Based Estimator Approach for HIV Feedback Control,” Optimal Control Applications and Methods, Vol. 27, No. 2, 2006, pp. 93 121.
 J. J. Kutch, P. Gurfil, “Optimal Control of HIV Infection with a ContinuouslyMutating Viral Population,” Proceedings of the 2002 American Control Conference, Anchorage, Vol. 5, 2002, pp. 40334038.
 P. Borrow, A. Tishon, S. Lee, J. Xu, I. S. Grewal, M. B. Oldstone and R. A. Flavell, “CD40LDeficient Mice Show Deficits in Antiviral Immunity and Have an ImPaired Memory CD8? CTL,” Journal of Experimental Medicine, Vol. 183, No. 5, 1996, pp. 21292142.
 H. H. Mehne, M. H. Farahi and A. V. Kamyad, “MILP Modelling for the Time Optimal Control Problem in The Case of Multiple Targets,” Optimal Control Applications and Methods, Vol. 27, No. 2, 2005, pp. 7791.